Hurtukova D. Dear healthcare provider letter regarding important safety and incompatibility information for Treanda^® (bedamustine HCl) injection (45 mg/0.5 mL or 180 mg/2 mL solution). North Wales, PA: Teva Pharmaceuticals USA; 2015 Mar 9. From the FDA website. Accessed 2015 Mar 12.